|
How to Cite 1. For In-Text Citation (Materials & Methods): 2. For Key Resources Table: |
||
|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. We strive to reply to |
| Formula | C43H44ClFN4O11S3 |
||||||
| Molecular Weight | 943.48 | CAS No. | 388082-78-8 | ||||
| Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (105.99 mM) | ||||
| Water | Insoluble | ||||||
| In vivo (Add solvents to the product individually and in order) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
|||||||
| Description | Lapatinib ditosylate monohydrate (Lapatinib ditoluenesulfonate monohydrate, Lapatinib tosilate, Lapatinib tosilate hydrate)is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways, used for treatment of solid tumours such as breast and lung cancer. | ||||||
|---|---|---|---|---|---|---|---|
| Targets |
|
|
| Effects of lapatinib on cell proliferation and apoptosis in NB4 cells [ Oncology Letters, November 3, 2017, 235-242] | PubMed: 29387217 |
| Treatment of cancer cells with Lapatinib negatively regulates general translation and induces stress granules formation [ PLoS One, May 4, 2020, e0231894] | PubMed: 32365111 |
| Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer [ Oncotarget, March 20, 2015, 5678-5694] | PubMed: 25691057 |
| Enhanced antitumor activity of lapatinib against triple-negative breast cancer via loading in human serum albumin [ Int J Biol Macromol, 2024, 282(Pt 2):136760] | PubMed: 39437943 |
| HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction [ Int J Mol Sci, 2023, 24(7)6228] | PubMed: 37047202 |
| Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2 [ Biochem Biophys Rep, 2023, 34:101436] | PubMed: 36824069 |
| RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy [ Cancer Discov, 2022, 12(1):204-219] | PubMed: 34544753 |
| Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets [ Nat Commun, 2022, 13(1):6481] | PubMed: 36309506 |
| Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer [ Nat Chem Biol, 2022, 10.1038/s41589-022-00984-x] | PubMed: 35273398 |
| Sustained oncogenic signaling in the cytostatic state enables targeting of non-proliferating persistent cancer cells [ Cancer Res, 2022, can.21.2908] | PubMed: 35792658 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.